Compare Repligen Corporation Common Stock (RGEN) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Ryanair Holdings plc — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while Ryanair Holdings plc trades at $51.75 (market cap $25.64B). The key difference: Ryanair Holdings plc is far larger — about 2.3× Repligen Corporation Common Stock's market cap, and Ryanair Holdings plc pays a 1.75% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Ryanair Holdings plc for 72 Days on average.
| RGEN | RYAAY | |
|---|---|---|
Market Cap | $11.31B | $25.64B |
Volume | 1,216,919 | 2,272,403 |
Sector | Health | Industrials |
52-Week High | $194.57 | $73.82 |
52-Week Low | $102.87 | $51.33 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $11.20B | $22.70B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Ryanair Holdings (RYAAY) trades at $52.84, down 0.3% on the day, with a bearish technical signal despite attractive valuation metrics including a P/E of 12.86 and EV/EBITDA of 5.68. The company reported mixed Q2 2026 earnings with a slight miss on EPS expectations but maintains strong profitability with 12.13% net margins. Recent news highlights CEO commentary on potential airfare increases due to high oil prices and Boeing MAX 10 certification delays.
RYAAY presents a compelling value opportunity with strong fundamentals and analyst support (64.7% buy ratings), though near-term headwinds include fuel cost volatility and operational challenges. The stock's current bearish technical positioning near support levels may offer entry points for long-term investors seeking exposure to Europe's leading low-cost carrier.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
